Analysts at Swiss bank Vontobel said the 2025 guidance was conservative, which was an expected stance taken by Roche. Total operating profit, adjusted for one-offs, came in at 20.8 billion Swiss ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for 2025. Sales in 2024 totaled $68.7 billion, which beat the Zacks Consensus ...

Schinecker said Roche is expecting a hit of around 1.2 billion Swiss francs ($1.32 billion) in biosimilars in line with last year, which he said was "very much digestible." Sales rose 3% last year ...

Sales at Roche rose 3% last year to 60.50 billion Swiss francs ($66.72 billion). Adjusting for currency movements, sales were up 7%, with growth in both its pharmaceuticals and diagnostics ...

Roche Holding, a Swiss multinational pharmaceutical and diagnostic giant, acquired the business in 2008 for $3.4 billion and has expanded its reach. Ventana had gone public 12 years earlier ...

Roche is to bolster its cancer pipeline with the $1.7 billion acquisition of Ignyta. The San Diego based biotech firm’s biggest asset is entrectinib, a selective tyrosine kinase inhibitor being ...

Hoffmann-La Roche Ltd is a major player in the global ... The global position sensor market is estimated to reach USD 19.02 billion in 2030 from USD 13.25 billion in 2025, at a CAGR of 7.5% ...

[Operator Instructions] One last remark, if you would like to follow the presented slides on your end as well, please feel free to go to roche.com ... impact was CHF1.1 billion, so exactly in ...